Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues

(2008) Judey Pretorius et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Neuroprotection in Parkinson’s disease: Myth or reality?

(2008) Tiffini Voss et al.   Current Neurology and Neuroscience Reports

Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk

(2007) Karen M. Powers et al.   MOVEMENT DISORDERS

Disease-modifying drugs and Parkinson's disease

(2007) Hervé Allain et al.   PROGRESS IN NEUROBIOLOGY

Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness

(2006) Moussa B H Youdim et al.   BRITISH JOURNAL OF PHARMACOLOGY